N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice

Pharmacological Research

Volumn 89, Issue , 2014, Pages 1-10

  Ciaglia, Elena ^a,b   Pisanti, Simona ^a,b   Picardi, Paola ^a,b   Laezza, Chiara ^c,d   Sosa, Silvio ^e   Tubaro, Aurelia ^e   Vitale, Mario ^a   Gazzerro, Patrizia ^b   Malfitano, Anna Maria ^a,b   Bifulco, Maurizio ^a,b  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cytotoxicity; ERK; Inflammation; iPA; NK cells; STAT5

Indexed keywords

6 N (3,3 DIMETHYLALLYL)ADENOSINE; CROTON OIL; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D; RANTES; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CD69 ANTIGEN; ANTIINFLAMMATORY AGENT; CYTOKINE; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NCR2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DERMATITIS; DOSE RESPONSE; DRUG POTENCY; EAR EDEMA; HUMAN; HUMAN CELL; IMMUNOCYTOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANTIGEN EXPRESSION; CELL ACTIVATION; CELL ACTIVITY; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; LEUKOCYTE MIGRATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; EDEMA; K562 CELL LINE; METABOLISM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; EDEMA; HUMANS; INTERLEUKIN-2; ISOPENTENYLADENOSINE; K562 CELLS; KILLER CELLS, NATURAL; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; STAT5 TRANSCRIPTION FACTOR;

EID: 84905437109     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.07.003     Document Type: Article

References (47)

1. J.R. Faust, and J.F. Dice Evidence for isopentenyladenine modification on a cell cycle-regulated protein J Biol Chem 266 1991 9961 9970
2. D.M. Burns, C.P. Rodi, and P.F. Agris Natural occurrence of an inhibitor of mammalian cell growth in human and mouse cells of normal and tumor origin Cancer Biochem Biophys 1 6 1976 269 280
3. M. Bifulco, A.M. Malfitano, M.C. Proto, A. Santoro, M.G. Caruso, and C. Laezza Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug Anticancer Agents Med Chem 8 2008 200 204
4. C. Laezza, M. Notarnicola, M.G. Caruso, C. Messa, M. Macchia, and S. Bertini et al. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation FASEB J 20 3 2006 412 418
5. C. Laezza, M.G. Caruso, T. Gentile, M. Notarnicola, A.M. Malfitano, and T. Di Matola et al. N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1 Int J Cancer 124 6 2009 1322 1329
6. C. Laezza, A.M. Malfitano, T. Di Matola, P. Ricchi, and M. Bifulco Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells Mol Carcinog 49 10 2010 892 901
7. S. Pisanti, P. Picardi, E. Ciaglia, L. Margarucci, R. Ronca, and A. Giacomini et al. Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation FASEB J 28 3 2014 1132 1144 10.1096/fj.13-238238
8. E. Ciaglia, S. Pisanti, P. Picardi, C. Laezza, A.M. Malfitano, and A. D'Alessandro et al. N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation J Leukoc Biol 94 6 2013 1207 1219
9. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini Functions of natural killer cells Nat Immunol 9 5 2008 503 510
10. L.L. Lanier NK cell recognition Annu Rev Immunol 23 2005 225 274
11. E. Vivier, J.A. Nunès, and F. Vély Natural killer cell signaling pathways Science 306 5701 2004 1517 1519
12. M. Thurnher, O. Nussbaumer, and G. Gruenbacher Novel aspects of mevalonate pathway inhibitors as antitumor agents Clin Cancer Res 18 13 2012 3524 3531
13. R.C. Gallo, J. Whang-Peng, and S. Perry Isopentenyladenosine stimulates and inhibits mitosis of human lymphocytes treated with phytohemagglutinin Science 165 3891 1969 400 402
14. A. Tubaro, P. Dri, G. Delbello, C. Zilli, and R. Della Loggia The croton oil ear test revisited Agents Actions 17 3-4 1986 347 349
15. Y. Taguchi, T. Kondo, M. Watanabe, M. Miyaji, H. Umehara, and Y. Kozutsumi et al. Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase Blood 104 10 2004 3285 3293
16. B.V. Dons'koi, V.P. Chernyshov, and D.V. Osypchuk Measurement of NK activity in whole blood by the CD69 up-regulation after co-incubation with K562, comparison with NK cytotoxicity assays and CD107a degranulation assay J Immunol Methods 372 1-2 2011 187 195
17. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 2013;4:69. http://dx.doi.org/10.3389/fimmu.2013.00069. eCollection 2013.
18. D. Pende, C. Cantoni, P. Rivera, M. Vitale, R. Castriconi, and S. Marcenaro et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin Eur J Immunol 31 4 2001 1076 1086
19. C. Fauriat, E.O. Long, H.G. Ljunggren, and Y.T. Bryceson Regulation of human NK-cell cytokine and chemokine production by target cell recognition Blood 115 11 2010 2167 2176
20. J.X. Lin, P. Li, D. Liu, H.T. Jin, J. He, and M. Ata Ur Rasheed et al. Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function Immunity 36 4 2012 586 599
21. C. Li, B. Ge, M. Nicotra, J.N. Stern, H.D. Kopcow, and X. Chen et al. JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity Proc Natl Acad Sci U S A 105 8 2008 3017 3022
22. T.K. Yu, E.G. Caudell, C. Smid, and E.A. Grimm IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway J Immunol 164 12 2000 6244 6251
23. L. Chiossone, C. Vitale, F. Cottalasso, S. Moretti, B. Azzarone, and L. Moretta et al. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells Blood 109 9 2007 3767 3775
24. X. Chen, D.S. Allan, K. Krzewski, B. Ge, H. Kopcow, and J.L. Strominger CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells Proc Natl Acad Sci U S A 103 27 2006 10346 10351
25. S. Liang, J. Zhang, H. Wei, R. Sun, and Z. Tian Differential roles of constitutively activated ERK1/2 and NF-kappa B in cytotoxicity and proliferation by human NK cell lines Int Immunopharmacol 5 5 2005 839 848
26. C.A. Alvarez-Breckenridge, J. Yu, R. Price, M. Wei, Y. Wang, and M.O. Nowicki et al. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon J Virol 86 8 2012 4566 4577
27. A. Moretta, C. Bottino, M. Vitale, D. Pende, C. Cantoni, and M.C. Mingari et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis Annu Rev Immunol 19 2001 197 223
28. C.C. Blad, J.K. von Frijtag Drabbe Künzel, H. de Vries, T. Mulder-Krieger, S. Bar-Yehuda, and P. Fishman et al. Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl) adenosine Purinergic Signal 7 4 2011 453 462
29. R. Sorrentino, A. Pinto, and S. Morello The adenosinergic system in cancer: key therapeutic target Oncoimmunology 2 1 2013
30. T. Priebe, C.D. Platsoucas, and J.A. Nelson Adenosine receptors and modulation of natural killer cell activity by purine nucleosides Cancer Res 50 14 1990 4328 4331
31. A. Harish, G. Hohana, P. Fishman, O. Arnon, and S. Bar-Yehuda A3 adenosine receptor agonist potentiates natural killer cell activity Int J Oncol 23 4 2003 1245 1249
32. P.K. Yadav, C. Chen, and Z. Liu Potential role of NK cells in the pathogenesis of inflammatory bowel disease J Biomed Biotechnol 2011 2011 348530
33. F. Ciccia, G. Guggino, A. Rizzo, A. Ferrante, S. Raimondo, and A. Giardina et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome Ann Rheum Dis. 71 2 2012 295 301 10.1136/ard.2011.154013
34. L. Chiche, J.M. Forel, G. Thomas, C. Farnarier, F. Vely, and M. Bléry et al. The role of natural killer cells in sepsis J Biomed Biotechnol 2011 2011 986491
35. M. Emoto, M. Miyamoto, I. Yoshizawa, Y. Emoto, U.E. Schaible, and E. Kita et al. Critical role of NK cells rather than V alpha 14(+)NKT cells in lipopolysaccharide-induced lethal shock in mice J Immunol 169 3 2002 1426 1432
36. A.R. Kerr, L.A. Kirkham, A. Kadioglu, P.W. Andrew, P. Garside, and H. Thompson et al. Identification of a detrimental role for NK cells in pneumococcal pneumonia and sepsis in immunocompromised hosts Microbes Infect 7 5-6 2005 845 852
37. B. Badgwell, R. Parihar, C. Magro, J. Dierksheide, T. Russo, and W.E. Carson 3rd Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection Surgery 132 2 2002 205 212
38. S. Kossmann, M. Schwenk, M. Hausding, S.H. Karbach, M.I. Schmidgen, and M. Brandt et al. Angiotensin II-induced vascular dysfunction depends on interferon-γ-driven immune cell recruitment and mutual activation of monocytes and NK-cells Arterioscler Thromb Vasc Biol 33 6 2013 1313 1319
39. C. Ple, M. Barrier, L. Amniai, P. Marquillies, J. Bertout, and A. Tsicopoulos et al. Natural killer cells accumulate in lung-draining lymph nodes and regulate airway eosinophilia in a murine model of asthma Scand J Immunol 72 2 2010 118 127
40. S.J. Lin, L.Y. Chang, D.C. Yan, Y.J. Huang, T.J. Lin, and T.Y. Lin Decreased intercellular adhesion molecule-1 (CD54) and L-selectin (CD62L) expression on peripheral blood natural killer cells in asthmatic children with acute exacerbation Allergy 58 1 2003 67 71
41. F.D. Shi, H.G. Ljunggren, A. La Cava, and L. Van Kaer Organ-specific features of natural killer cells Nat Rev Immunol. 11 10 2011 658 671 doi: 10.1038/nri3065 Review
42. C. Ottaviani, F. Nasorri, C. Bedini, O. de Pità, G. Girolomoni, and A. Cavani CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation Eur J Immunol 36 1 2006 118 128
43. Monfrecola G, Lembo S, Cantelli M, Ciaglia E, Scarpato L, Fabbrocini G, et al. The effect of visible blue light on the differentiation of dendritic cells in vitro. Biochimie 2014;(February). pii: S0300-9084(14)00053-4.
44. A. Dassano, M. Mancuso, P. Giardullo, L.D. Cecco, P. Ciuffreda, and E. Santaniello et al. N(6)-isopentenyladenosine and analogs activate the NRF2-mediated antioxidant response Redox Biol 2 2014 580 589
45. C. Costantini, and M.A. Cassatella The defensive alliance between neutrophils and NK cells as a novel arm of innate immunity J Leukoc Biol 89 2 2011 221 233
46. D. Mittal, F. Sacchaeri, E. Venereau, T. Pusteria, and M.E. Bianchi et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells EMBO J 29 2010 2242 2252
47. J.L. Guerriero, D. Ditsworth, J.M. Catanzaro, G. Sabino, M.B. Furie, and R.R. Kew et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity J Immunol 186 6 2011 3517 3526 10.4049/jimmunol.1003267